Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 32Head & Neck 9Gynecologic 7Thoracic 5Breast 4Tumor-Agnostic 2Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Non-squamous Non-small-cell Lung Cancer 1

Interventions

Carboplatin 351pembrolizumab 327Pemetrexed 249Cisplatin 221Paclitaxel 149Nivolumab 139durvalumab 134Docetaxel 112osimertinib 111atezolizumab 107Specimen Handling 91Radiotherapy 89Drug Therapy 87Magnetic Resonance Spectroscopy 78Etoposide 78Radiosurgery 74Gemcitabine 72Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 53cemiplimab 47tislelizumab 46Blood Specimen Collection 43Cetuximab 35Taxes 34Injections 33Biopsy 33Standard of Care 32Platinum 32Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
camrelizumab × Thoracic × 1 year × Clear all
NCT04768075 2026-05-20

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Guangdong Association of Clinical Trials

Phase 3 Completed
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03083041 2026-03-03

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
210 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04619433 2025-09-23

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
48 enrolled
Thoracic

Non-squamous Non-small-cell Lung Cancer

NCT07053215 2025-07-08

Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC

The First Hospital of Hebei Medical University

Phase NA Completed
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Terminated
25 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡